Structure-Based Design, Synthesis, and In Vivo Antinociceptive Effects of Selective A1 Adenosine Receptor Agonists.

Our previous work discovered that combining the appropriate 5'- and N6-substitution in adenosine derivatives leads to the highly selective human A1 adenosine receptor (hA1AR) agonists or highly potent dual hA1AR agonists and hA3AR antagonists. In order to explore novel dual adenosine receptor ligands, a series of N6-substituted-5'-pyrazolyl-adenosine and 2-chloro-adenosine derivatives were synthesized and assayed in vitro at all ARs. The N6-(±)-endo-norbornyl derivative 12 was the most potent and selective at A1AR and effective as an analgesic in formalin test in mice, but none of the 5'-pyrazolyl series compounds showed a dual behavior at hA1 and hA3AR. Molecular modeling studies rationalized the structure-activity relationships and the selectivity profiles of the new series of A1AR agonists. Interestingly, an unexpected inverted binding mode of the N6-tetrahydrofuranyl derivative 14 was hypothesized to explain its low affinity at A1AR.

[1]  E. Novellino,et al.  Exploring the Role of N6-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice ∇. , 2017, Journal of medicinal chemistry.

[2]  K. Jacobson,et al.  Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms , 2017, Neuropharmacology.

[3]  Arthur Christopoulos,et al.  Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity , 2017, Cell.

[4]  J. Sawynok Adenosine receptor targets for pain , 2016, Neuroscience.

[5]  K. Jacobson,et al.  Ocular Purine Receptors as Drug Targets in the Eye. , 2016, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[6]  R. Petrelli,et al.  Development of C-Methyl Branched Purine Ribonucleoside Analogs: Chemistry, Biological Activity and Therapeutic Potential. , 2016, Current medicinal chemistry.

[7]  K. Jacobson,et al.  Medicinal chemistry of adenosine, P2Y and P2X receptors , 2016, Neuropharmacology.

[8]  K. Jacobson,et al.  Identification of A3 adenosine receptor agonists as novel non‐narcotic analgesics , 2016, British journal of pharmacology.

[9]  P. Fishman,et al.  The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis , 2016, Clinical Rheumatology.

[10]  Rebecca K Donegan,et al.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. , 2016, Journal of medicinal chemistry.

[11]  M. Malcangio,et al.  Chronic Pain: New Insights in Molecular and Cellular Mechanisms , 2015, BioMed research international.

[12]  Riccardo Petrelli,et al.  5'-C-Ethyl-tetrazolyl-N(6)-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists. , 2015, Journal of medicinal chemistry.

[13]  N. Mercuri,et al.  Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice , 2014, Experimental Neurology.

[14]  A. Usiello,et al.  The A1 adenosine receptor as a new player in microglia physiology , 2014, Glia.

[15]  Silvia Paoletta,et al.  Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. , 2013, Journal of medicinal chemistry.

[16]  R. Petrelli,et al.  5'-Chloro-5'-deoxy-(±)-ENBA, a Potent and Selective Adenosine A1 Receptor Agonist, Alleviates Neuropathic Pain in Mice Through Functional Glial and Microglial Changes without Affecting Motor or Cardiovascular Functions , 2012, Molecules.

[17]  Kenneth A Jacobson,et al.  Controlling murine and rat chronic pain through A3 adenosine receptor activation , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  K. Jacobson,et al.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists. , 2012, Drug discovery today.

[19]  K. Jacobson,et al.  Emerging adenosine receptor agonists – an update , 2011, Expert opinion on emerging drugs.

[20]  E. Bulger,et al.  Increased Neutrophil Adenosine A3 Receptor Expression Is Associated With Hemorrhagic Shock and Injury Severity in Trauma Patients , 2011, Shock.

[21]  K. Jacobson,et al.  Truncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element. , 2011, ACS medicinal chemistry letters.

[22]  Richard J. Hall,et al.  Docking performance of fragments and druglike compounds. , 2011, Journal of medicinal chemistry.

[23]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[24]  Y. Yen,et al.  Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents. , 2011, European journal of medicinal chemistry.

[25]  R. Stevens,et al.  Agonist bound structure of the human adenosine A2a receptor , 2011 .

[26]  B. Fredholm,et al.  Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. , 2008, The Journal of allergy and clinical immunology.

[27]  L. Jeong,et al.  Alternative and improved syntheses of highly potent and selective A3 adenosine receptor agonists, CI-IB-MECA and Thio-CI-IB-MECA , 2007, Archives of pharmacal research.

[28]  F. Rossi,et al.  The antinociceptive effect of 2-chloro-2′-C-methyl-N6-cyclopentyladenosine (2′-Me-CCPA), a highly selective adenosine A1 receptor agonist, in the rat , 2007, PAIN.

[29]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[30]  Riccardo Petrelli,et al.  Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. , 2005, Journal of medicinal chemistry.

[31]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[32]  J. Richardson,et al.  The penultimate rotamer library , 2000, Proteins.

[33]  M. Judge,et al.  N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. , 1999, Journal of medicinal chemistry.

[34]  C. Martini,et al.  2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. , 1998, Journal of medicinal chemistry.

[35]  B. Fredholm,et al.  Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[36]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[37]  K. Klotz,et al.  2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

[38]  R. Egan,et al.  Modification of the 5' position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5'-(N-substituted)carboxamides. , 1980, Journal of medicinal chemistry.

[39]  D. Dubuisson,et al.  The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.

[40]  CharlesPowell White NOMENCLATURE AND CLASSIFICATION. , 1901 .

[41]  K. Jacobson,et al.  Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. , 2015, Brain : a journal of neurology.

[42]  G. Cristalli,et al.  Photoaffinity Labeling of A 1-adenosine Receptors * , 2011 .

[43]  K. Klotz,et al.  Adenosine Receptor with Antinociceptive Effects in Mice , 2009 .

[44]  K. Klotz,et al.  5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. , 2008, Bioorganic & medicinal chemistry.

[45]  E. Elzein,et al.  A1 adenosine receptor agonists and their potential therapeutic applications. , 2008, Expert opinion on investigational drugs.

[46]  Zhihe Li,et al.  Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor--efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF). , 2004, Bioorganic & medicinal chemistry letters.

[47]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .